Abstract
To the Editor: A transdermal TM-V (scopolamine) programmed-delivery system has recently been released as treatment for the prevention of nausea and vomiting associated with motion sickness. The National Registry of Drug-Induced Ocular Side Effects has had five case reports of adverse ocular effects secondary to this drug-delivery system. Two of the reported cases were bilateral mydriasis causing bilateral narrow-angle glaucoma. One patient required surgery; the other was treated medically. Since this medication is now often used on ships by those susceptible to motion sickness, physicians aboard ships should have available 4 per cent topical ocular pilocarpine and 0.25 per.
Original language | English (US) |
---|---|
Pages (from-to) | 1079 |
Number of pages | 1 |
Journal | New England Journal of Medicine |
Volume | 307 |
Issue number | 17 |
DOIs | |
State | Published - Oct 21 1982 |
ASJC Scopus subject areas
- General Medicine